Last reviewed · How we verify
Vaccine Candidate #3
Vaccine Candidate #3 is a Biologic drug developed by Pfizer. It is currently in Phase 2 development.
Takeda's Vaccine Candidate #3, also known as TetraVax-DV-TV003, is being studied for its potential to prevent Dengue Fever, Dengue, Ebola Virus, Malaria, Falciparum, and Influenza. A Phase 3 trial, NCT03999996, is evaluating the long-term safety and antibody persistence of this vaccine, as well as the impact of a booster dose.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vaccine Candidate #3 |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Pain
- Fatigue
- Headache
- Swelling
- Upper respiratory tract infection
- Redness
- Malaise
- Pyrexia
- Irritability
- Decreased appetite
- Somnolence
- Arthralgia
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers (PHASE1)
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (PHASE1, PHASE2)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein (PHASE1)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine Candidate #3 CI brief — competitive landscape report
- Vaccine Candidate #3 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Vaccine Candidate #3
What is Vaccine Candidate #3?
Who makes Vaccine Candidate #3?
What development phase is Vaccine Candidate #3 in?
What are the side effects of Vaccine Candidate #3?
Related
- Manufacturer: Pfizer — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing